Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,...

Ogkologos - 20 Νοεμβρίου, 2024

EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of...

Ogkologos - 19 Νοεμβρίου, 2024

Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible...

Ogkologos - 18 Νοεμβρίου, 2024

How Do Black People with Cancer View Clinical Research?

Ogkologos - 15 Νοεμβρίου, 2024

Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS...

Ogkologos - 15 Νοεμβρίου, 2024

Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma

Ogkologos - 14 Νοεμβρίου, 2024

iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with...

Ogkologos - 14 Νοεμβρίου, 2024

FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma

Ogkologos - 13 Νοεμβρίου, 2024

EMA Recommends Granting a Marketing Authorisation for Catumaxomab

Ogkologos - 12 Νοεμβρίου, 2024

Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched...

Ogkologos - 11 Νοεμβρίου, 2024

1...646566...440 Σελίδα 65 από 440

MOST POPULAR

Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...

10 Απριλίου, 2024

News digest – dinosaur bone cancer, YouTube junk food ad ban...

8 Αυγούστου, 2020

No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In...

17 Νοεμβρίου, 2025

FDA Recognises OncoKB Database of Molecular Tumour Marker Information

8 Οκτωβρίου, 2021

Φόρτωση περισσοτέρων

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,...

EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of...

Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible...

How Do Black People with Cancer View Clinical Research?

Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS...

Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma

iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with...

FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma

EMA Recommends Granting a Marketing Authorisation for Catumaxomab

Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched...

MOST POPULAR

Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...

News digest – dinosaur bone cancer, YouTube junk food ad ban...

No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In...

FDA Recognises OncoKB Database of Molecular Tumour Marker Information

HOT NEWS

pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue...

Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with...

Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence...

Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ